Industry Focus Transcripts

The toy industry’s biggest two companies are telling two very different stories this quarter.

Why you might want to check out Novocure, Foundation Medicine, and Celgene sooner rather than later.

Find out why our energy experts think General Motors, NV5, and Transocean have the potential to see huge wins in the long run.

Yes, Tesla missed its Model 3 production estimates by a whopping 83% this quarter -- but that’s not the whole story.

Two Fools discuss the new devices Roku and Google announced last week and what they could mean for each company's business.

It may be "old media", but the famous newspaper is flourishing under the current presidential administration.

Industry Focus looks at bank earnings, important metrics, and catalysts that could move bank stocks higher.

Green energy might seem to be taking off, but oil is far from dead, and the market is undervaluing old industries.

In today's episode, we offer up some insights into the risks and rewards associated with owning pharmaceutical dividend darlings Johnson & Johnson, AbbVie, and Pfizer.

Demand for diamonds is reportedly falling, but this luxury brand is on a bullish run.

America is far from the only country in the energy game, and investors might want to diversify their portfolios with these solid companies.

The streaming video pioneer has seen massive growth in the last few years, and it's showing no signs of slowing down as it dives into international markets.

Find out what's so exciting about investing in Mastercard, Square, and Berkshire Hathaway.

Unpacking Axovant Sciences big Alzheimer’s disease disappointment, plus Pfizer accuses Johnson & Johnson of unfairly increasing healthcare costs.

The company will give viewers access to 10,000 live sporting events, 500 films, and over 7,000 television episodes. Traditional pay-TV subscriber numbers are on the decline, and CEO Bob Iger sees this streaming transition as his last major priority before retirement.

The much-maligned drugmaker is making progress, but it's not out of the woods yet. Plus, why Keryx Pharmaceuticals shares tumbled despite winning a key FDA approval.

While a combined entity would make for a formidable competitor in the wireless industry, the prospect appears increasingly unlikely despite two attempts in three years.

Utilities are often overlooked in favor of flashier companies, but all kinds of long-term investors could benefit from some exposure to the sector.

Despite Tencent's new 10% stake in Snap, the Snapchat operator continues to show discouraging results.

A flurry of news has investors clamoring to add Nektar Therapeutics to their portfolios.